Edinburgh Research Explorer

Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis: Running title : TRAF6/NFkB inhibition reduced breast cancer metastasis

Research output: Contribution to journalArticle

  • Ryan T. Bishop
  • Silvia Marino
  • Giovana Carrasco
  • Boya Li
  • Richard J Allen
  • Anna Sparatore
  • Penelope D Ottewell
  • Patrick Mollat
  • Andrew Sims
  • Mattia Capulli
  • Ning Wang
  • Aymen Idris

Related Edinburgh Organisations

Original languageEnglish
JournalCancer letters
Early online date28 May 2020
Publication statusE-pub ahead of print - 28 May 2020


Tumour necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in breast cancer and osteoclastic bone destruction. Here, we report that 6877002, a verified small-molecule inhibitor of TRAF6, reduced metastasis, osteolysis and osteoclastogenesis in models of osteotropic human and mouse breast cancer. First, we observed that TRAF6 is highly expressed in osteotropic breast cancer cells and its level of expression was higher in patients with bone metastasis. Pre-exposure of osteoclasts and osteoblasts to non-cytotoxic concentrations of 6877002 inhibited cytokineinduced NFκB activation and osteoclastogenesis, and reduced the ability of osteotropic human MDA-MB-231 and mouse 4T1 breast cancer cells to support bone cell activity. 6877002 inhibited human MDA-MB-231-induced osteolysis in the mouse calvaria organ system, and reduced soft tissue and bone metastases in immuno-competent mice following intra-cardiac injection of mouse 4T1-Luc2 cells. Of clinical relevance, combined administration of 6877002 with Docetaxel reduced
metastasis and inhibited osteolytic bone damage in mice bearing 4T1-Luc2 cells. Thus, TRAF6 inhibitors such as 6877002 – alone or in combination with conventional chemotherapy - show promise for the treatment of metastatic breast cancer.

    Research areas

  • 6877002, NFkB, RANKL, CD40L, combinatin therapy

ID: 148458682